Public Profile

NEOPHARM

NEOPHARM, officially known as Neopharm Group, is a prominent player in the pharmaceutical industry, headquartered in Illinois, USA. Founded in 1998, the company has established itself as a leader in the development and distribution of innovative healthcare solutions, primarily focusing on oncology, neurology, and rare diseases. With a strong operational presence across North America and Europe, NEOPHARM is recognised for its commitment to advancing patient care through unique drug formulations and cutting-edge therapies. The company’s core offerings include a range of specialty pharmaceuticals that are distinguished by their efficacy and safety profiles. NEOPHARM has achieved significant milestones, including strategic partnerships and successful product launches, solidifying its market position as a trusted provider in the healthcare sector.

DitchCarbon Score

How does NEOPHARM's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

25

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

NEOPHARM's score of 25 is lower than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.

39%

Let us know if this data was useful to you

NEOPHARM's reported carbon emissions

NEOPHARM, headquartered in Illinois (IL), currently does not have publicly available carbon emissions data or specific reduction targets. Without reported emissions figures, it is challenging to assess their carbon footprint or climate commitments accurately. However, the absence of data may indicate a need for enhanced transparency in their sustainability practices. As the industry increasingly prioritises climate action, NEOPHARM may benefit from establishing clear emissions reduction goals and aligning with recognised frameworks to demonstrate their commitment to mitigating climate change.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. NEOPHARM's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for NEOPHARM is in IL, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

NEOPHARM is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers